{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:39:05Z","timestamp":1792201145201,"version":"4.4.0"},"reference-count":188,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Atrial fibrillation (AF) and cancer are increasingly recognized as interrelated conditions, with cancer patients showing elevated incidences of AF, and there is evidence that AF may sometimes precede cancer diagnoses. This comprehensive review investigates the epidemiology, pathophysiology, and management challenges associated with AF in cancer patients. Epidemiologically, several cancers are more closely related to increased rates of AF, including lung, colorectal, gastrointestinal, and hematologic malignancies. Mechanistically, both AF and cancer share pathophysiological pathways centered on inflammation, oxidative stress, and common cardiovascular risk factors, such as hypertension, obesity, and diabetes. The inflammatory microenvironment in tumors, marked by increased cytokines and growth factors, promotes atrial remodeling and AF susceptibility. Elevated reactive oxygen species (ROS) levels, driven by the metabolic demands of cancer, further contribute to atrial fibrosis and structural changes. Moreover, many anticancer treatments exacerbate AF risk. Management of AF in cancer patients presents many unique challenges and requires a multidisciplinary approach. Rate and rhythm control strategies are complicated by potential drug\u2013drug interactions and limited data surrounding early implementation of rhythm control strategies in cancer patients. Interventional approaches such as catheter ablation, though effective in maintaining sinus rhythm, carry significant perioperative risk in patients with malignancy. Stroke prevention with anticoagulants is essential but requires cautious administration to avoid heightened bleeding risks, particularly in patients undergoing chemotherapy. Further, the limited applicability of standard risk stratification tools like CHA2DS2-VASc in this population complicate decisions regarding anticoagulation. This review highlights the bidirectional relationship between AF and cancer, the difficulties in management, and the critical need for further research in this field.<\/jats:p>","DOI":"10.3390\/jcm13247753","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T08:04:14Z","timestamp":1734595454000},"page":"7753","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Atrial Fibrillation and Cancer\u2014Epidemiology, Mechanisms, and Management"],"prefix":"10.3390","volume":"13","author":[{"given":"Nathaniel E.","family":"Davis","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7956-0574","authenticated-orcid":false,"given":"Narut","family":"Prasitlumkum","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0365-9471","authenticated-orcid":false,"given":"Nicholas Y.","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1093\/eurheartj\/ehae222","article-title":"Coexisting atrial fibrillation and cancer: Time trends and associations with mortality in a nationwide Dutch study","volume":"45","author":"Chen","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s11886-022-01769-3","article-title":"Atrial Fibrillation and Cancer Patients: Mechanisms and Management","volume":"24","author":"Madnick","year":"2022","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e016836","DOI":"10.1161\/JAHA.120.016836","article-title":"New Cancer Diagnosis After Bleeding in Anticoagulated Patients with Atrial Fibrillation","volume":"9","author":"Pardal","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e29929","DOI":"10.1016\/j.heliyon.2024.e29929","article-title":"Global association of incidence between atrial fibrillation and the major gastrointestinal cancers: An analysis based on the 2019 Global burden of disease study","volume":"10","author":"Huang","year":"2024","journal-title":"Heliyon"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e009543","DOI":"10.1161\/JAHA.118.009543","article-title":"Atrial Fibrillation and Risk of Cancer: A Danish Population-Based Cohort Study","volume":"7","author":"Vinter","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Ostenfeld, E.B., Erichsen, R., Pedersen, L., Farkas, D.K., Weiss, N.S., and S\u00f8rensen, H.T. (2014). Atrial Fibrillation as a Marker of Occult Cancer. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0102861"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/eurheartj\/ehab745","article-title":"Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: A SEER-Medicare analysis","volume":"43","author":"Guha","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1002\/cam4.4105","article-title":"Prevalence, trends, and outcomes of atrial fibrillation in hospitalized patients with metastatic cancer: Findings from a national sample","volume":"10","author":"Han","year":"2021","journal-title":"Cancer Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.amjcard.2015.01.540","article-title":"Relation Between Cancer and Atrial Fibrillation (from the REasons for Geographic and Racial Differences in Stroke Study)","volume":"115","author":"Lakoski","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100026","DOI":"10.1016\/j.rpth.2022.100026","article-title":"Atrial fibrillation and cancer: Prevalence and relative risk from a nationwide study","volume":"7","author":"Ay","year":"2023","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1001\/jamacardio.2016.0280","article-title":"Risk of Malignant Cancer Among Women with New-Onset Atrial Fibrillation","volume":"1","author":"Conen","year":"2016","journal-title":"JAMA Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"8985273","DOI":"10.1155\/2019\/8985273","article-title":"Association of Cancer and the Risk of Developing Atrial Fibrillation: A Systematic Review and Meta-Analysis","volume":"2019","author":"Yuan","year":"2019","journal-title":"Cardiol. Res. Pract."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/20009666.2020.1726571","article-title":"Atrial fibrillation and cancer; understanding the mysterious relationship through a systematic review","volume":"10","author":"Lateef","year":"2020","journal-title":"J. Community Hosp. Intern. Med. Perspect."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1016\/j.jacc.2021.04.110","article-title":"Racial and Ethnic Considerations in Patients with Atrial Fibrillation: JACC Focus Seminar 5\/9","volume":"78","author":"Norby","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.cjca.2024.02.016","article-title":"Are Socioeconomic Factors Associated with Atrial Fibrillation Sex-Dependent? A Narrative Review","volume":"40","author":"Zhou","year":"2024","journal-title":"Can. J. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/cncr.33470","article-title":"Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: A nationwide cohort study","volume":"127","author":"Pastori","year":"2021","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"7623","DOI":"10.18632\/oncotarget.24143","article-title":"Impact of atrial fibrillation on the development of ischemic stroke among cancer patients classified by CHA2DS2-VASc score-a nationwide cohort study","volume":"9","author":"Hu","year":"2018","journal-title":"Oncotarget"},{"key":"ref_18","first-page":"1","article-title":"Atrial fibrillation in cancer patients who develop stroke","volume":"8","author":"Khamis","year":"2022","journal-title":"Cardio-Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.amjcard.2017.11.027","article-title":"In-Hospital Cerebrovascular Outcomes of Patients with Atrial Fibrillation and Cancer (from the National Inpatient Sample Database)","volume":"121","author":"Elbadawi","year":"2018","journal-title":"Am. J. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ijcard.2015.10.166","article-title":"Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy","volume":"203","author":"Lee","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/j.amjcard.2017.08.038","article-title":"Usefulness of CHADS2 and CHA2DS2-VASc Scores for Stroke Prediction in Patients with Cancer and Atrial Fibrillation","volume":"120","author":"Patell","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1177\/2047487318759858","article-title":"CHA2DS2-VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer","volume":"25","author":"Carlson","year":"2018","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s00277-018-3346-1","article-title":"Incidence, predictive factors, management, and survival impact of atrial fibrillation in non-Hodgkin lymphoma","volume":"97","author":"Sorigue","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_24","first-page":"4933","article-title":"Reactive oxygen species mediated oxidative stress links diabetes and atrial fibrillation","volume":"17","author":"Liang","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.jacc.2014.02.555","article-title":"Atrial Remodeling and Atrial Fibrillation: Recent advances and translational perspectives","volume":"63","author":"Nattel","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1161\/01.CIR.0000103131.70301.4F","article-title":"Inflammation as a Risk Factor for Atrial Fibrillation","volume":"108","author":"Aviles","year":"2003","journal-title":"Circulation"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1161\/CIRCULATIONAHA.107.744466","article-title":"Metabolic Syndrome and Risk of Development of Atrial Fibrillation: The Niigata preventive medicine study","volume":"117","author":"Watanabe","year":"2008","journal-title":"Circulation"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Tadic, M., Genger, M., Cuspidi, C., Belyavskiy, E., Frydas, A., Dordevic, A., Morris, D.A., V\u00f6lkl, J., Parwani, A.S., and Pieske, B. (2019). Phasic Left Atrial Function in Cancer Patients Before Initiation of Anti-Cancer Therapy. J. Clin. Med., 8.","DOI":"10.3390\/jcm8040421"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11739-008-0124-4","article-title":"First diagnosis of colorectal or breast cancer and prevalence of atrial fibrillation","volume":"3","author":"Guzzetti","year":"2008","journal-title":"Intern. Emerg. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.semcdb.2017.05.023","article-title":"ROS signalling in the biology of cancer","volume":"80","author":"Moloney","year":"2018","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jaccao.2021.08.011","article-title":"Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis","volume":"3","author":"Leiva","year":"2021","journal-title":"JACC CardioOncology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","article-title":"Ibrutinib-Associated Atrial Fibrillation","volume":"4","author":"Ganatra","year":"2018","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Yang, X., Li, X., Yuan, M., Tian, C., Yang, Y., Wang, X., Zhang, X., Sun, Y., He, T., and Han, S. (2018). Anticancer Therapy-Induced Atrial Fibrillation: Electrophysiology and Related Mechanisms. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.01058"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1111\/cas.15068","article-title":"Reactive oxygen species in cancer: Current findings and future directions","volume":"112","author":"Nakamura","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3109\/10715761003667554","article-title":"Reactive oxygen species in cancer","volume":"44","author":"Liou","year":"2010","journal-title":"Free Radic. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1477-3163-5-14","article-title":"Reactive oxygen species: Role in the development of cancer and various chronic conditions","volume":"5","author":"Waris","year":"2006","journal-title":"J. Carcinog."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0828-282X(06)70314-2","article-title":"Reactive oxygen species and vascular remodelling in hypertension: Still alive","volume":"22","author":"Xu","year":"2006","journal-title":"Can. J. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"453892","DOI":"10.1155\/2010\/453892","article-title":"Role of Reactive Oxygen Species in the Progression of Type 2 Diabetes and Atherosclerosis","volume":"2010","author":"Kaneto","year":"2010","journal-title":"Mediat. Inflamm."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1089\/met.2015.0095","article-title":"Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic Strategies","volume":"13","author":"Manna","year":"2015","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Seo, Y., Kim, J.-S., Park, E.-S., and Ryu, E. (2018). Assessment of the awareness and knowledge of cancer survivors regarding the components of metabolic syndrome. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0199142"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000495698","article-title":"Diabetes and Metabolic Syndrome in Survivors of Childhood Cancer","volume":"91","author":"Friedman","year":"2019","journal-title":"Horm. Res. Paediatr."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: Cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/FJC.0000000000001182","article-title":"Atrial Fibrillation Induced by Anticancer Drugs and Underling Mechanisms","volume":"80","author":"Burashnikov","year":"2021","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.acvd.2023.02.005","article-title":"Atrial fibrillation, cancer and anticancer drugs","volume":"116","author":"Font","year":"2023","journal-title":"Arch. Cardiovasc. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"19","DOI":"10.15420\/ecr.2015.10.01.19","article-title":"Chemotherapy-related Cardiomyopathy","volume":"10","author":"Piper","year":"2015","journal-title":"Eur. Cardiol. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Ran, T., Chen, J., She, Q., Mu, Y., Zhang, M., Mao, M., Zuo, Z., and Li, J. (2024). Anthracycline-induced arrhythmias in breast cancer therapy: A meta-analysis of single-arm trials. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0303208"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amjcard.2024.02.017","article-title":"Atrial Fibrillation Amplifies Heart Failure Risk in Anthracycline Treated Cancer Patients: Stacking Risk Factors in the Vulnerable","volume":"218","author":"Ilkhanoff","year":"2024","journal-title":"Am. J. Cardiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jacep.2016.08.009","article-title":"Burden of Cardiac Arrhythmias in Patients with Anthracycline-Related Cardiomyopathy","volume":"3","author":"Mazur","year":"2017","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.amjcard.2023.11.038","article-title":"Impact of Atrial Fibrillation on Heart Failure in Patients Treated with Anthracycline Chemotherapy","volume":"211","author":"Onoue","year":"2023","journal-title":"Am. J. Cardiol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Cardinale, D., Iacopo, F., and Cipolla, C.M. (2020). Cardiotoxicity of Anthracyclines. Front. Cardiovasc. Med., 7.","DOI":"10.3389\/fcvm.2020.00026"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/157340311799960645","article-title":"Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment","volume":"7","author":"Volkova","year":"2011","journal-title":"Curr. Cardiol. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular Toxicities Associated with Ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Caldeira, D., Alves, D., Costa, J., Ferreira, J.J., Pinto, F.J., Caldeira, D., Alves, D., Costa, J., Ferreira, J.J., and Pinto, F.J. (2019). Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0211228"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/hon.3126","article-title":"Predictors of ibrutinib-associated atrial fibrillation: 5-year follow-up of a prospective study","volume":"41","author":"Mattiello","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaccao.2023.09.002","article-title":"Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia","volume":"5","author":"Quartermaine","year":"2023","journal-title":"JACC CardioOncology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s40199-023-00464-0","article-title":"Cardiac safety profile of type II kinase inhibitors: Analysis of post-marketing reports from databases of European Medicine Agency & World Health Organization","volume":"31","author":"Khurana","year":"2023","journal-title":"DARU J. Pharm. Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1080\/14740338.2023.2204226","article-title":"Pharmacovigilance analysis of cardiac risks associated with Bruton tyrosine kinase inhibitors","volume":"22","author":"Zhai","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s11886-023-01916-4","article-title":"Diagnosis and Management of Cardiovascular Effects of Bruton\u2019s Tyrosine Kinase Inhibitors","volume":"25","author":"Aghel","year":"2023","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1200\/JCO.22.02830","article-title":"Zanubrutinib Versus Ibrutinib in Symptomatic Waldenstr\u00f6m Macroglobulinemia: Final Analysis from the Randomized Phase III ASPEN Study","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10840-023-01575-z","article-title":"Comparative arrhythmia patterns among patients on tyrosine kinase inhibitors","volume":"67","author":"Wei","year":"2023","journal-title":"J. Interv. Card. Electrophysiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1080\/17474086.2023.2223926","article-title":"Impact of atrial fibrillation in onco-hematological patients in Europe: A targeted literature review","volume":"16","author":"Bas","year":"2023","journal-title":"Expert Rev. Hematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.clinthera.2023.11.014","article-title":"Cardiovascular Adverse Events Associated with Second-generation Bruton Tyrosine Kinase Inhibitor Therapy: A Systematic Review and Meta-analysis","volume":"46","author":"Proskuriakova","year":"2024","journal-title":"Clin. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","article-title":"Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase","volume":"142","author":"Xiao","year":"2020","journal-title":"Circulation"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.hrthm.2019.04.008","article-title":"Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium","volume":"16","author":"Jiang","year":"2019","journal-title":"Heart Rhythm"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/clc.20904","article-title":"Melphalan-Induced Supraventricular Tachycardia: Incidence and Risk Factors","volume":"34","author":"Feliz","year":"2011","journal-title":"Clin. Cardiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1200\/JCO.2004.00.1792","article-title":"Concurrent Cetuximab, Cisplatin, and Concomitant Boost Radiotherapy for Locoregionally Advanced, Squamous Cell Head and Neck Cancer: A Pilot Phase II Study of a New Combined-Modality Paradigm","volume":"24","author":"Pfister","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ajh.20441","article-title":"High-dose cyclophosphamide and MESNA infusion can cause acute atrial fibrillation","volume":"80","author":"Ifran","year":"2005","journal-title":"Am. J. Hematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1200\/JCO.1991.9.1.192","article-title":"Cisplatin-induced atrial fibrillation","volume":"9","author":"Menard","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0167-8140(88)90296-4","article-title":"Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil","volume":"13","author":"Eskilsson","year":"1988","journal-title":"Radiother. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0169-5002(00)00194-X","article-title":"Activity and toxicity of gemcitabine and gemcitabine+vinorelbine in advanced non-small-cell lung cancer elderly patients","volume":"31","author":"Gridelli","year":"2001","journal-title":"Lung Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djp440","article-title":"Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention","volume":"102","author":"Albini","year":"2010","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jccase.2019.08.005","article-title":"Atrial fibrillation observed in a patient with esophageal cancer treated with fluorouracil","volume":"20","author":"Moriyama","year":"2019","journal-title":"J. Cardiol. Cases"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0936-6555(98)80033-2","article-title":"Supraventricular arrhythmia: A complication of 5-fluorouracil therapy","volume":"10","author":"Aziz","year":"1998","journal-title":"Clin. Oncol."},{"key":"ref_76","first-page":"e403","article-title":"Myocardial Ischemia Induced by 5-Fluorouracil: A Prospective Electrocardiographic and Cardiac Biomarker Study","volume":"26","author":"Schou","year":"2020","journal-title":"Oncologist"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Focaccetti, C., Bruno, A., Magnani, E., Bartolini, D., Principi, E., Dallaglio, K., Bucci, E.O., Finzi, G., Sessa, F., and Noonan, D.M. (2015). Effects of 5-Fluorouracil on Morphology, Cell Cycle, Proliferation, Apoptosis, Autophagy and ROS Production in Endothelial Cells and Cardiomyocytes. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0115686"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"6666","DOI":"10.12659\/MSM.910537","article-title":"Mitochondrial Dynamics in Rat Heart Induced by 5-Fluorouracil","volume":"24","author":"Zhang","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00280-011-1669-x","article-title":"5-Fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity","volume":"69","author":"Jensen","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Wei, M., Wang, P., Zhu, X., Morishima, M., Liu, Y., Zheng, M., Liu, G., Osanai, H., Yoshimura, K., and Kume, S. (2023). Electrophysiological evaluation of an anticancer drug gemcitabine on cardiotoxicity revealing down-regulation and modification of the activation gating properties in the human rapid delayed rectifier potassium channel. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0280656"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1093\/oncolo\/oyab035","article-title":"Cardiotoxicity from Capecitabine Chemotherapy: Prospective Study of Incidence at Rest and During Physical Exercise","volume":"27","author":"Lestuzzi","year":"2022","journal-title":"Oncologist"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e012798","DOI":"10.1136\/bmjopen-2016-012798","article-title":"Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: A retrospective study of 452 consecutive patients with metastatic breast cancer","volume":"6","author":"Polk","year":"2016","journal-title":"BMJ Open"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10549-022-06753-7","article-title":"The association of trastuzumab with atrial fibrillation and heart failure in breast cancer patients in routine clinical practice: A population-based propensity score matching and competing risk model analysis","volume":"198","author":"Wu","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Mauro, E., Luc\u00e0, F., Tetta, C., Parise, O., Parrini, I., Parise, G., Rao, C.M., Matteucci, F., Micali, L.R., and Gulizia, M.M. (2022). Breast Cancer and Atrial Fibrillation. J. Clin. Med., 11.","DOI":"10.3390\/jcm11051417"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e029361","DOI":"10.1161\/JAHA.123.029361","article-title":"Adverse Cardiovascular Events Associated with Cyclin-Dependent Kinase 4\/6 Inhibitors in Patients with Metastatic Breast Cancer","volume":"12","author":"Fradley","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/cvr\/cvz020","article-title":"Cardiac arrhythmia considerations of hormone cancer therapies","volume":"115","author":"Barber","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40259-019-00382-1","article-title":"Different Cardiotoxicity of Palbociclib and Ribociclib in Breast Cancer: Gene Expression and Pharmacological Data Analyses, Biological Basis, and Therapeutic Implications","volume":"33","author":"Santoni","year":"2019","journal-title":"BioDrugs"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Papageorgiou, C., Zagouri, F., Tampakis, K., Georgakopoulou, R., Manios, E., Kafouris, P., Benetos, G., Koutagiar, I., Anagnostopoulos, C., and Dimopoulos, M.A. (2021). Vascular Inflammation and Cardiovascular Burden in Metastatic Breast Cancer Female Patients Receiving Hormonal Treatment and CDK 4\/6 Inhibitors or Everolimus. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.638895"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41698-023-00360-5","article-title":"AKT\/mTOR signaling modulates resistance to endocrine therapy and CDK4\/6 inhibition in metastatic breast cancers","volume":"7","author":"Hodge","year":"2023","journal-title":"npj Precis. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1002\/cam4.3938","article-title":"Cardiovascular adverse events associated with BRAF versus BRAF\/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries","volume":"10","author":"Guha","year":"2021","journal-title":"Cancer Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e005443","DOI":"10.1161\/CIRCEP.117.005443","article-title":"Cancer Treatment\u2013Induced Arrhythmias","volume":"10","author":"Buza","year":"2017","journal-title":"Circ. Arrhythmia Electrophysiol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2022.01.096","article-title":"Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: JACC: CardioOncology State-of-the-Art Review","volume":"4","author":"Glen","year":"2022","journal-title":"JACC CardioOncology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e198890","DOI":"10.1001\/jamanetworkopen.2019.8890","article-title":"Cardiovascular Adverse Events Associated with BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis","volume":"2","author":"Mincu","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"6637","DOI":"10.1002\/cam4.5438","article-title":"Arrhythmic events associated with immune checkpoint inhibitors therapy: A real-world study based on the Food and Drug Administration Adverse Event Reporting System database","volume":"12","author":"Liu","year":"2023","journal-title":"Cancer Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40264-021-01086-8","article-title":"Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance","volume":"44","author":"Mascolo","year":"2021","journal-title":"Drug Saf."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"584","DOI":"10.4330\/wjc.v12.i11.584","article-title":"Cardiac adverse events of immune checkpoint inhibitors in oncology patients: A systematic review and meta-analysis","volume":"12","author":"Nso","year":"2020","journal-title":"World J. Cardiol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2019.3113","article-title":"Factors Associated with Immune Checkpoint Inhibitor\u2013Related Myocarditis","volume":"5","author":"Zamami","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Chen, C., Chen, T., Liang, J., Guo, X., Xu, J., Zheng, Y., Guo, Z., Chi, L., Wei, L., and Chen, X. (2021). Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.616505"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"100252","DOI":"10.1016\/j.esmoop.2021.100252","article-title":"Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States","volume":"6","author":"Jain","year":"2021","journal-title":"ESMO Open"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1160\/TH16-07-0531","article-title":"The impact of CD4+CD28null T-lymphocytes on atrial fibrillation and mortality in patients with chronic heart failure","volume":"117","author":"Sulzgruber","year":"2017","journal-title":"Thromb. Haemost."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/bjh.19497","article-title":"Atrial arrhythmias following CAR-chimeric antigen receptor T-cell therapy: Incidence, risk factors and biomarker profile","volume":"205","author":"Shouval","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/eurheartj\/ehac106","article-title":"Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies","volume":"43","author":"Totzeck","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Qi, K., Yan, Z., Cheng, H., Chen, W., Wang, Y., Wang, X., Cao, J., Zhang, H., Sang, W., and Zhu, F. (2021). An Analysis of Cardiac Disorders Associated with Chimeric Antigen Receptor T Cell Therapy in 126 Patients: A Single-Centre Retrospective Study. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.691064"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Ahmad, J., Thurlapati, A., Thotamgari, S., Grewal, U.S., Sheth, A.R., Gupta, D., Beedupalli, K., and Dominic, P. (2022). Anti-cancer Drugs Associated Atrial Fibrillation\u2014An Analysis of Real-World Pharmacovigilance Data. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.739044"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/ajh.22114","article-title":"Inflammation, TNF\u03b1 and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia","volume":"86","author":"Aue","year":"2011","journal-title":"Am. J. Hematol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1345\/aph.1P044","article-title":"Myocarditis During Lenalidomide Therapy","volume":"44","author":"Carver","year":"2010","journal-title":"Ann. Pharmacother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1097\/SLA.0000000000000960","article-title":"New-onset Atrial Fibrillation Post-surgery for Esophageal and Junctional Cancer","volume":"260","author":"Zaborowski","year":"2014","journal-title":"Ann. Surg."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Semeraro, G.C., Meroni, C.A., Cipolla, C.M., and Cardinale, D.M. (2021). Atrial Fibrillation after Lung Cancer Surgery: Prediction, Prevention and Anticoagulation Management. Cancers, 13.","DOI":"10.3390\/cancers13164012"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Fabiani, I., Colombo, A., Bacchiani, G., Cipolla, C.M., and Cardinale, D.M. (2019). Incidence, Management, Prevention and Outcome of Post-Operative Atrial Fibrillation in Thoracic Surgical Oncology. J. Clin. Med., 9.","DOI":"10.3390\/jcm9010037"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1245\/s10434-022-12690-y","article-title":"Risk Factors and In-Hospital Outcomes of Perioperative Atrial Fibrillation for Patients with Cancer: A Meta-Analysis","volume":"30","author":"Inoue","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/jso.2930500405","article-title":"Postoperative atrial fibrillation in cancer surgery: Preoperative risks and clinical outcome","volume":"50","author":"Gibbs","year":"1992","journal-title":"J. Surg. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1097\/JS9.0000000000001006","article-title":"Development and external validation of a novel model for predicting new clinically important atrial fibrillation after thoracoscopic anatomical lung cancer surgery: A multicenter retrospective cohort study","volume":"110","author":"Tong","year":"2024","journal-title":"Int. J. Surg."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(23)01689-6","article-title":"Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): An international randomised trial","volume":"402","author":"Conen","year":"2023","journal-title":"Lancet"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijrobp.2023.08.011","article-title":"Incident Atrial Fibrillation and Survival Outcomes in Esophageal Cancer following Radiotherapy","volume":"118","author":"Miller","year":"2023","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ejhf.654","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines","volume":"19","author":"Zamorano","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jamaoncol.2022.4202","article-title":"Association of Sinoatrial Node Radiation Dose with Atrial Fibrillation and Mortality in Patients with Lung Cancer","volume":"8","author":"Kim","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"110085","DOI":"10.1016\/j.radonc.2024.110085","article-title":"Pulmonary vein dose and risk of atrial fibrillation in patients with non-small cell lung cancer following definitive radiotherapy: An NI-HEART analysis","volume":"192","author":"Walls","year":"2024","journal-title":"Radiother. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pharmthera.2018.04.009","article-title":"Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms","volume":"189","author":"Alexandre","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1111\/pace.14830","article-title":"Outcome of cancer patients after atrial fibrillation ablation: Insights from the China-AF registry","volume":"46","author":"Peng","year":"2023","journal-title":"Pacing Clin. Electrophysiol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/jce.12619","article-title":"Pulmonary Vein Isolation for Atrial Fibrillation in the Postpneumonectomy Population: A Feasibility, Safety, and Outcomes Study","volume":"26","author":"Kanmanthareddy","year":"2015","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jacep.2020.08.009","article-title":"Catheter Ablation in Patients with Neuroendocrine (Carcinoid) Tumors and Carcinoid Heart Disease","volume":"7","author":"Shabtaie","year":"2021","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10840-020-00745-7","article-title":"Safety of catheter ablation of atrial fibrillation in cancer survivors","volume":"60","author":"Giustozzi","year":"2021","journal-title":"J. Interv. Card. Electrophysiol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10840-023-01677-8","article-title":"Safety and efficacy of catheter ablation for atrial fibrillation in cancer survivors: A systematic review and meta-analysis","volume":"67","author":"Costa","year":"2023","journal-title":"J. Interv. Card. Electrophysiol."},{"key":"ref_126","first-page":"749","article-title":"Atrial Fibrillation in Active Cancer Patients: Expert Position Paper and Recommendations","volume":"72","author":"Mitroi","year":"2019","journal-title":"Rev. Espanola Cardiol. (Engl. Ed.)"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40264-014-0258-4","article-title":"Cancer Chemotherapy and Cardiac Arrhythmias: A Review","volume":"38","author":"Tamargo","year":"2015","journal-title":"Drug Saf."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(16)31277-6","article-title":"Rhythm control in atrial fibrillation","volume":"388","author":"Piccini","year":"2016","journal-title":"Lancet"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1161\/CIRCULATIONAHA.106.177292","article-title":"ACC\/AHA\/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation","volume":"114","author":"Fuster","year":"2006","journal-title":"Circulation"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/CIR.0000000000000040","article-title":"2014 AHA\/ACC\/HRS Guideline for the Management of Patients with Atrial Fibrillation: Executive Summary","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1016\/j.hrthm.2015.09.019","article-title":"2015 ACC\/AHA\/HRS guideline for the management of adult patients with supraventricular tachycardia","volume":"13","author":"Page","year":"2016","journal-title":"Heart Rhythm"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.2007.12.2705","article-title":"Breast Cancer Treatment Outcome with Adjuvant Tamoxifen Relative to Patient CYP2D6 and CYP2C19 Genotypes","volume":"25","author":"Schroth","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1158\/0008-5472.CAN-04-4103","article-title":"Role of Hepatic Cytochrome P450s in the Pharmacokinetics and Toxicity of Cyclophosphamide: Studies with the Hepatic Cytochrome P450 Reductase Null Mouse","volume":"65","author":"Pass","year":"2005","journal-title":"Cancer Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1161\/CIR.0b013e3182a88099","article-title":"Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions: A scientific statement from the American Heart Association","volume":"128","author":"Lipshultz","year":"2013","journal-title":"Circulation"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1021\/acsmedchemlett.3c00266","article-title":"Platinum\u2013Acridine Agents with High Activity in Cancers Expressing the Solute Carrier MATE1 (SLC47A1)","volume":"14","author":"Zhang","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Uddin, M.E., Talebi, Z., Chen, S., Jin, Y., Gibson, A.A., Noonan, A.M., Cheng, X., Hu, S., and Sparreboom, A. (2021). In Vitro and In Vivo Inhibition of MATE1 by Tyrosine Kinase Inhibitors. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13122004"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.bcp.2010.08.019","article-title":"Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity","volume":"80","author":"Nakamura","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"15S","DOI":"10.1177\/1074248410367792","article-title":"Clinical Pharmacology of Dronedarone: Implications for the Therapy of Atrial Fibrillation","volume":"15","author":"Dorian","year":"2010","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_139","first-page":"E199","article-title":"2014 AHA\/ACC\/HRS Guideline for the Management of Patients with Atrial Fibrillation","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00003088-200544030-00005","article-title":"Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs","volume":"44","author":"Zhou","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1093\/annonc\/mdq761","article-title":"Potential drug interactions in cancer therapy: A prevalence study using an advanced screening method","volume":"22","author":"Swart","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.hrthm.2021.04.007","article-title":"Flecainide-induced QRS complex widening correlates with negative inotropy","volume":"18","author":"Evangelista","year":"2021","journal-title":"Heart Rhythm"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"A19","DOI":"10.1016\/0002-9149(93)90021-4","article-title":"Clinical pharmacokinetics of sotalol","volume":"72","author":"Hanyok","year":"1993","journal-title":"Am. J. Cardiol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/ijc.33119","article-title":"Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors","volume":"147","author":"Rmilah","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40959-023-00171-4","article-title":"Efficacy and safety of catheter ablation for atrial fibrillation in patients with history of cancer","volume":"9","author":"Ganatra","year":"2023","journal-title":"Cardio-Oncol."},{"key":"ref_146","first-page":"790","article-title":"Feasibility of radiofrequency ablation for cancer patients with atrial fibrillation","volume":"49","author":"Wang","year":"2021","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"euad263","DOI":"10.1093\/europace\/euad263","article-title":"Outcomes and readmissions in patients with cancer undergoing catheter ablation for atrial fibrillation","volume":"25","author":"Agarwal","year":"2023","journal-title":"Europace"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1080\/00325481.2023.2218188","article-title":"Safety of catheter ablation for atrial fibrillation in patients with cancer: A nationwide cohort study","volume":"135","author":"Thotamgari","year":"2023","journal-title":"Postgrad. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"A15839","DOI":"10.1161\/circ.146.suppl_1.15839","article-title":"Abstract 15839: Complication and Readmission Outcome of Atrial Fibrillation Catheter Ablation Among Cancer Patients","volume":"146","author":"Wu","year":"2022","journal-title":"Circulation"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1161\/01.CIR.0000146952.49223.11","article-title":"Radiation Exposure During Catheter Ablation of Atrial Fibrillation","volume":"110","author":"Lickfett","year":"2004","journal-title":"Circulation"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s10840-023-01469-0","article-title":"Fluoroless catheter ablation of atrial fibrillation: A step-by-step workflow","volume":"66","author":"Enriquez","year":"2023","journal-title":"J. Interv. Card. Electrophysiol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/s41591-024-03114-3","article-title":"Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study","volume":"30","author":"Ekanem","year":"2024","journal-title":"Nat. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/europace\/euaa087","article-title":"Prevalence and in-hospital outcomes of patients with malignancies undergoing de novo cardiac electronic device implantation in the USA","volume":"22","author":"Mohamed","year":"2020","journal-title":"EP Europace"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/europace\/euac112","article-title":"Rate and nature of complications with leadless transcatheter pacemakers compared with transvenous pacemakers: Results from an Italian multicentre large population analysis","volume":"25","author":"Palmisano","year":"2023","journal-title":"EP Europace"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/jamacardio.2021.2621","article-title":"Contemporaneous Comparison of Outcomes Among Patients Implanted with a Leadless vs Transvenous Single-Chamber Ventricular Pacemaker","volume":"6","author":"Piccini","year":"2021","journal-title":"JAMA Cardiol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.hrthm.2018.04.022","article-title":"Comparative study of acute and mid-term complications with leadless and transvenous cardiac pacemakers","volume":"15","author":"Cantillon","year":"2018","journal-title":"Heart Rhythm"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"euad269","DOI":"10.1093\/europace\/euad269","article-title":"Comparison of in-hospital outcomes and complications of leadless pacemaker and traditional transvenous pacemaker implantation","volume":"25","author":"Alhuarrat","year":"2023","journal-title":"Europace"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/jce.15863","article-title":"Leadless versus transvenous single-chamber ventricular pacemakers: 3 year follow-up of the Micra CED study","volume":"34","author":"Crossley","year":"2023","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/europace\/euad016","article-title":"Two-year outcomes of leadless vs. transvenous single-chamber ventricular pacemaker in high-risk subgroups","volume":"25","author":"Boveda","year":"2023","journal-title":"EP Europace"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1088\/0031-9155\/47\/16\/304","article-title":"Influence of high-energy photon beam irradiation on pacemaker operation","volume":"47","author":"Mouton","year":"2002","journal-title":"Phys. Med. Biol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ctrv.2005.05.002","article-title":"Radiotherapy to patients with artificial cardiac pacemakers","volume":"31","author":"Sundar","year":"2005","journal-title":"Cancer Treat. Rev."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.clon.2010.08.031","article-title":"Radiation Therapy with Implanted Cardiac Pacemaker Devices: A Clinical and Dosimetric Analysis of Patients and Proposed Precautions","volume":"23","author":"Wadasadawala","year":"2011","journal-title":"Clin. Oncol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1001\/jama.1975.03260140074020","article-title":"Cardiac pacemakers. Does radiation therapy affect performance?","volume":"234","author":"Walz","year":"1975","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1753944719860676","DOI":"10.1177\/1753944719860676","article-title":"Predicting outcomes in patients with cancer and atrial fibrillation","volume":"13","author":"Gutierrez","year":"2019","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amjcard.2022.06.044","article-title":"Validation of Embolic and Bleeding Risk Scores in Patients With Atrial Fibrillation and Cancer","volume":"180","author":"Pousa","year":"2022","journal-title":"Am. J. Cardiol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jaccao.2022.08.014","article-title":"Arterial Thromboembolism in Patients with AF and CHA2DS2-VASc Score 0-2 With and Without Cancer","volume":"5","author":"Leader","year":"2023","journal-title":"JACC CardioOncology"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.hjc.2023.06.005","article-title":"Risk of arterial thromboembolism, bleeding and mortality in atrial fibrillation patients with comorbid cancer: A systematic review and meta-analysis","volume":"74","author":"Balomenakis","year":"2023","journal-title":"Hell. J. Cardiol."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Parrini, I., Luc\u00e0, F., Rao, C.M., Parise, G., Micali, L.R., Musumeci, G., La Meir, M., Colivicchi, F., Gulizia, M.M., and Gelsomino, S. (2022). Superiority of Direct Oral Anticoagulants over Vitamin K Antagonists in Oncological Patients with Atrial Fibrillation: Analysis of Efficacy and Safety Outcomes. J. Clin. Med., 11.","DOI":"10.3390\/jcm11195712"},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Truong, B., Hornsby, L., Fox, B., Chou, C., Zheng, J., and Qian, J. (2024). Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Cancer: A Target Trial Emulation from SEER-Medicare Database. Cardiovasc. Drugs Ther.","DOI":"10.1007\/s10557-024-07589-7"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/bloodadvances.2017010694","article-title":"Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation","volume":"2","author":"Shah","year":"2018","journal-title":"Blood Adv."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Chai-Adisaksopha, C., Watanabe, A.H., Dilokthornsakul, P., Navaravong, L., Witt, D.M., and Chaiyakunapruk, N. (2023). Impact of type of anticoagulant on clinical outcomes in cancer patients who had atrial fibrillation. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-38071-3"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e012540","DOI":"10.1161\/JAHA.119.012540","article-title":"Non\u2013Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis","volume":"8","author":"Deng","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"e008951","DOI":"10.1161\/CIRCOUTCOMES.122.008951","article-title":"Comparative Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin Among Adults with Cancer and Atrial Fibrillation","volume":"15","author":"Mehta","year":"2022","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/bloodadvances.2018024893","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: Optimal management of anticoagulation therapy","volume":"2","author":"Witt","year":"2018","journal-title":"Blood Adv."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/fcp.12769","article-title":"Tyrosine kinase inhibitors and direct oral anticoagulants: In vitro evaluation of drug\u2013drug interaction mediated by P-glycoprotein","volume":"36","author":"Lafaie","year":"2022","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s11239-023-02879-7","article-title":"Screening for clinically relevant drug-drug interactions between direct oral anticoagulants and antineoplastic agents: A pharmacovigilance approach","volume":"56","author":"Truong","year":"2023","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"106507","DOI":"10.1016\/j.ejps.2023.106507","article-title":"Anlotinib and fruquintinib co-administrated with warfarin increases the risk of bleeding: Studied from pharmacokinetic and pharmacodynamic perspectives","volume":"188","author":"Fang","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1080\/00498254.2022.2118643","article-title":"In vivo evaluation of pharmacokinetic drug\u2013drug interactions between fluorinated pyrimidine anticancer drugs, 5-fluorouracil and capecitabin, and an anticoagulant, warfarin","volume":"52","author":"Hasegawa","year":"2022","journal-title":"Xenobiotica"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.amjcard.2023.06.068","article-title":"Left Atrial Appendage Closure Outcomes in Patients with Cancer at a Single Tertiary Center","volume":"202","author":"Kumar","year":"2023","journal-title":"Am. J. Cardiol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40959-023-00192-z","article-title":"Utilization and short-term outcomes of percutaneous left atrial appendage occlusion in patients with cancer","volume":"9","author":"Zhang","year":"2023","journal-title":"Cardio-Oncol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaccao.2022.10.016","article-title":"Left Atrial Appendage Occlusion in Patients with Atrial Fibrillation and Cancer","volume":"5","author":"Shabtaie","year":"2023","journal-title":"JACC CardioOncology"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jtcvs.2019.01.095","article-title":"Amiodarone for prevention of atrial fibrillation following esophagectomy","volume":"158","author":"Tisdale","year":"2019","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jtcvs.2010.01.026","article-title":"A randomized, controlled study of amiodarone for prevention of atrial fibrillation after transthoracic esophagectomy","volume":"140","author":"Tisdale","year":"2010","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.athoracsur.2014.06.069","article-title":"Postoperative Atrial Fibrillation Prophylaxis After Lung Surgery: Systematic Review and Meta-Analysis","volume":"98","author":"Riber","year":"2014","journal-title":"Ann. Thorac. Surg."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.athoracsur.2011.12.096","article-title":"Amiodarone Significantly Decreases Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer","volume":"94","author":"Riber","year":"2012","journal-title":"Ann. Thorac. Surg."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.jacc.2014.07.944","article-title":"2014 ACC\/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery","volume":"64","author":"Fleisher","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_187","unstructured":"EHRA Scientific Committee Task Force, and ESC Scientific Document Group (2016). European Heart Rhythm Association (EHRA)\/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). Europace, 19, 190\u2013225."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular Events Among Adults Treated with Chimeric Antigen Receptor T-Cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/24\/7753\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:55:24Z","timestamp":1760115324000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/24\/7753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":188,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["jcm13247753"],"URL":"https:\/\/doi.org\/10.3390\/jcm13247753","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]}}}